Compare · ABT vs DNTH
ABT vs DNTH
Side-by-side comparison of Abbott Laboratories (ABT) and Dianthus Therapeutics Inc. (DNTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and DNTH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 30.4x DNTH ($5.77B).
- Over the past year, ABT is down 19.1% and DNTH is up 407.6% - DNTH leads by 426.7 points.
- ABT has been more active in the news (10 items in the past 4 weeks vs 3 for DNTH).
- ABT has more recent analyst coverage (25 ratings vs 14 for DNTH).
- Company
- Abbott Laboratories
- Dianthus Therapeutics Inc.
- Price
- $100.68+1.91%
- $105.38+10.55%
- Market cap
- $175.37B
- $5.77B
- 1M return
- +11.09%
- +33.54%
- 1Y return
- -19.08%
- +407.61%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 10
- 3
- Recent ratings
- 25
- 14
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest DNTH
- EVP, CFO & CBO Savitz Ryan exercised 31,249 shares at a strike of $21.77 and sold $3,157,151 worth of shares (31,249 units at $101.03) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
- Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
- SVP, General Counsel and Sec. Veness Adam M exercised 30,000 shares at a strike of $17.88 and sold $2,423,958 worth of shares (30,000 units at $80.80) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- EVP, Head of R&D Randhawa Simrat exercised 26,530 shares at a strike of $18.85 and sold $2,404,077 worth of shares (26,530 units at $90.62) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dianthus Therapeutics to Participate in Two Investor Conferences
- SEC Form 4 filed by Director Lawton Alison Frances
- SEC Form 4 filed by Director Romano Steven J.